Kennedy Capital Management LLC Sells 17,741 Shares of AtriCure, Inc. $ATRC

Kennedy Capital Management LLC lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 614,387 shares of the medical device company’s stock after selling 17,741 shares during the quarter. Kennedy Capital Management LLC owned about 1.24% of AtriCure worth $20,133,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. US Bancorp DE grew its holdings in shares of AtriCure by 98.1% in the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company’s stock valued at $51,000 after purchasing an additional 789 shares in the last quarter. Strs Ohio bought a new position in AtriCure during the first quarter valued at $158,000. Ameritas Investment Partners Inc. grew its stake in shares of AtriCure by 6.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock worth $162,000 after buying an additional 312 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of AtriCure by 15.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,808 shares of the medical device company’s stock worth $190,000 after buying an additional 770 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of AtriCure in the 2nd quarter worth about $205,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Stock Up 2.8%

Shares of NASDAQ:ATRC opened at $36.31 on Thursday. The firm has a market capitalization of $1.81 billion, a PE ratio of -59.52 and a beta of 1.47. The business has a 50 day simple moving average of $35.05 and a two-hundred day simple moving average of $34.35. AtriCure, Inc. has a 1 year low of $28.29 and a 1 year high of $43.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.85.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative return on equity of 2.54% and a negative net margin of 5.55%.AtriCure’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, equities analysts predict that AtriCure, Inc. will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ATRC. Canaccord Genuity Group increased their price target on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.22.

Insider Activity

In other AtriCure news, Director Sven Wehrwein sold 4,967 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total value of $188,746.00. Following the completion of the sale, the director directly owned 34,374 shares of the company’s stock, valued at $1,306,212. The trade was a 12.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Justin J. Noznesky sold 5,166 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total transaction of $192,640.14. Following the completion of the transaction, the insider owned 78,798 shares in the company, valued at $2,938,377.42. This represents a 6.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 21,166 shares of company stock valued at $785,278. 3.50% of the stock is currently owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.